LONDON, Jan. 27, 2015 /PRNewswire/ -- This report analyzes the worldwide markets for Cell-Based Assays in US$ Million by the following Applications: Basic Research, ADME Testing, and Drug Discovery. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as -

BD Biosciences
Beckman Coulter, Inc.
BioVision, Inc.
Cisbio Bioassays
DiscoveRx Corporation

Download the full report: https://www.reportbuyer.com/product/552745/


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Basic Research I-3
ADME Testing I-3
Drug Discovery I-4


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Cell-based Assays: A Most Promising Area in Cellular Biology II-1
Table 1: Global Market for Cell-based Assays (2013):
Percentage Share Breakdown of Value Sales by Segment
(includes corresponding Graph/Chart) II-2

Table 2: Global Market for Cell-based Assays (2013):
Percentage Share Breakdown of Value Sales by End-User
(includes corresponding Graph/Chart) II-2
Developed Markets Dominate, While Asia-Pacific Lends Growth
Momentum II-2
Major Trends, Growth Drivers and Restraints II-3
Trends II-3
Growth Drivers II-4
Growth Restraints II-4
Growing Prominence of Cell-based Assays in Drug Discovery II-4
Cell-Based Assays Emerge as a Popular Tool in Basic Research II-6
Use of Cell-based Assays in ADME-Toxicity Testing Gains Traction II-6
Hepatotoxicity Testing Occupies Largest Market Share II-6
Cell-based Assays in HTS and UHTS II-7
Major Types of Cell-Based HTS Assays for Drug Screening II-8
High-Content Screening (HCS) - A Rapidly Expanding Screening
Technology in Cell-Based Assays II-8
High Content Screening - Key Application Areas II-9
HCS vs. HTS II-9
Outsourcing of Pharma R&D Gathers Momentum II-10
Table 3: Worldwide Annual Spending on Drugs by Category (2011
& 2015): Percentage Breakdown of Dollar Sales for Branded
Drugs, Generic Drugs, and Others (includes corresponding
Graph/Chart) II-11
Drug Discovery Outsourcing and Type of Services Outsourced II-11

2. MAJOR TRENDS & ISSUES II-12
Growing Inclination towards In-vitro Assays for Toxicology
Studies II-12
Time and Cost Benefits Drive Use of Cell-Based Assays over
Other Techniques II-12
Rising Number of Drug Targets Surge Demand for Cell-Based Assays II-12
Growing Focus on the Development of Reproducible and Robust
Cell-based Assays II-13
Stem Cells Exude Great Potential in Drug Toxicity Testing II-13
Stem Cell Research in Cardiovascular Repair Rife with Hurdles II-14
Increasing Use of Cell-Based Assays over Other Methods in
Toxicity Testing II-15
Functional Assays: An Effective Way of Predicting Specific
Toxic Effects II-15
GPCR Targets to Drive Growth in Functional Cell Assay Market II-15
Innovation in Screening Guarantees Success for Drug Discovery
Programs II-16
3D Cell Culture Technology to Put a New Spin on In Vitro Cell
Analyses II-16
3D-CRT with Capability of Tracking Real Time 3D Position of
Diffusing Nanoparticles II-16
Automated Multiplexing Platforms Present Growth Opportunities II-17
Miniaturized Cell-based Assays on the Horizon II-17
Rising Interest in Cell-based Assays Propels Development of
Improved Products II-17
Automation of Cell-based Assays: A Growing Trend II-18
Technology Advances in Drug Discovery Processes Spurs Cell-
Based Assay Market II-18
Development of Label-free Cell-based Assays: A Recent Trend in
Biological Assays II-18
Microfluidics Systems in Cell-based Assays II-19
Cell-Based Assays Likely to Gain from Microfluidic Devices II-19
Other Trends II-20
Raman Spectroscopy: An Attractive Analytical Tool for
Pharmaceutical Industry II-20
Fluorescence Spectroscopy for Cellular Imaging Analyses II-21
Cell-based Immunoassays: Novel Assay Technology for
Autoantibodies Detection II-21
Shift Away from Established Cell Lines to Primary Cells II-22
Role of Cell-based Assays in Personalized Medicine: A Research
Focus II-22

3. CELL-BASED ASSAYS - APPLICATION AREAS II-23
Cell-Based Assays in Drug Discovery II-23
Table 4: Global Drug Discovery Market (2013): Percentage
Share Breakdown of Revenues by Segment (includes
corresponding Graph/Chart) II-23
Drug Target Validation II-24
Lead Identification II-24
Lead Optimization II-24
Sources and Types of Cells Available for Drug Screening II-24
Cell-Based Assays in ADME Testing II-25
Table 5: Leading Causes of Failure During New Drug
Development: Percentage Share Breakdown by ADME/Tox Issues,
Insufficient Efficacy, Adverse Side Effects, and Commercial
Viability (includes corresponding Graph/Chart) II-26
Need for Better Models: A Major Factor Driving Innovation in
the Market II-26

4. CELL-BASED ASSAYS: AN OVERVIEW II-28
What Drives Advances in Cell-based Assays? II-28
Cell Culture Fundamentals II-28
An Insight into Cell Biology II-29
Cell-based Assays: Basic Facts II-29
Defining Cell-based Assays II-30
Assays II-30
Biological Assays II-30
Quantification of Biological Activity II-30
Cell-based Assays II-31
Cell Based Assays: Prerequisites for Proof of Concept II-31
List of Factors to be considered in Cell-Based Assays II-32
Contamination with Mycoplasma: A Critical Factor II-32
Modes of Contamination II-33
Prevention II-33
Uses of Cell-Based Assays II-33
Challenges II-34
Transient Transfection Cells II-34
Limitations II-34
Cell-based Assays: Product Segmentation II-34
Assay Kits II-35
Cell Function-Associated Assays II-35
Cell Growth-Associated Assays II-35
Select Methods of Evaluating Cell-Growth II-36
Various Types of Cell Growth Associated Assays: II-36
Cell Death-Associated Assays II-37
Lab Automation II-38
MIACA II-39

5. PRODUCT INTRODUCTIONS/INNOVATIONS II-40
InSphero Releases 3D InSight™ Cytotoxicity Assay Kit II-40
Clinigene Introduces Cell-Based Biomarker Assay II-40
BioVision Launches EZViable™ Calcein AM Cell Viability Assay
Kit and MTS Cell Proliferation Assay Kit II-40
Hepregen Rolls Out First Rat Hepatopactm Assay Kit for
Toxicology Applications II-40
Labstract Launches Cell-Based Assay Services II-40
Hepregen Unveils Human HepatoMune™ Assay Kit II-41
Molecular Devices Launches EarlyTox™ Cell Integrity Kit II-41
LGC Introduces cGMP Cell-based Assay Capability II-41
SymCel Rolls Out Commercial Label-Free Cell-Based Assay II-41
Platypus Technologies Introduces Oris™ Pro 96-Well Invasion Assay II-41
BioVision Launches Cell-Based Cholesterol Efflux Fluorometric
Assay Kit II-41
Promega Rolls Out GloMax® Discover Multimode Detection Plate
Reader System II-42
Hepregen Launches First Monkey Hepatopac™ Assay Kits II-42
DiscoveRx Launches New Human Primary Cell-Based T Cell
Autoimmune Panel II-42
Hepregen Introduces Multi-Donor Human Hepatopac™ Assay II-42
Hurel Introduces Cell-Based In Vitro Testing Product Suite II-42
Thermo Fisher Scientific Releases Three New High Content
Analysis Products II-42
Thermo Fisher Scientific Launches Novel Incubation Solution
for Cell-Based Research II-43
DiscoveRx Introduces InCELL Hunter™ Platform II-43
Cellectricon Launches Advanced Cell-Based Assay Systems II-43
BioTek Launches Gas Controller for Synergy™ Hybrid Multi-Mode
Microplate Readers II-43
Intertek Releases cGMP Cell-Based Assays II-43

6. RECENT INDUSTRY ACTIVITY II-44
Promethera Biosciences Collaborates with EMD Millipore II-44
Axxam and Cellectis Partner to Provide New Generation of Cell-
Based Assays II-44
TGR BioSciences and Abcam Enter into Licensing Agreement II-44
Viradux Research Enters into JV Partnership with Benalli II-44
Cellectricon Introduces Discovery Services Division II-44
PPD Announces Expansion of cGMP Cell-based Assay Laboratory II-45
Oxford Immunotec Enters into Licensing and Partnership
Agreements with Lophius Biosciences II-45
Evotec Takes Over Cell Culture Service II-45
GE Healthcare Inks Sublicense Agreement with Cellular Dynamics
for Cellular Assay Patents II-45
Discoverx Acquires BioSeek® II-45
CEVEC and CSS Enter into License Agreement II-45
Cyprotex Enters into Licensing Deal with Sigma® Life Science II-46
Medicyte to Collaborate with Reinnervate to Develop 3D Cell
Toxicity Assays II-46
Affymetrix Acquires eBioscience Holding Company II-46
SGS Inaugurates New Cell-Based Assay Laboratory II-46
Corning Acquires Majority of BD's Discovery Labware Unit II-46

7. FOCUS ON SELECT GLOBAL PLAYERS II-47
BD Biosciences (US) II-47
Beckman Coulter, Inc. (US) II-47
BioVision, Inc. (US) II-48
Cisbio Bioassays (US) II-48
DiscoveRx Corporation (US) II-49
EMD Millipore Corp. (US) II-49
Enzo Life Sciences, Inc. (US) II-50
Evotec AG (Germany) II-51
GE Healthcare Life Sciences (UK) II-51
New England Biolabs, Inc. (US) II-52
PerkinElmer, Inc. (US) II-52
Promega Corporation (US) II-53
ProQinase GmbH (Germany) II-54
Qiagen NV (The Netherlands) II-54
Sigma-Aldrich Corporation (US) II-55
StemCells, Inc. (US) II-55
Thermo Fisher Scientific, Inc. (US) II-56
Life Technologies Corp. (US) II-56
Xenometrix AG (Switzerland) II-57

8. GLOBAL MARKET PERSPECTIVE II-58
Table 6: World Recent Past, Current and Future Analysis for
Cell-Based Assays by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2013 through 2020
(includes corresponding Graph/Chart) II-58

Table 7: World Historic Review for Cell-Based Assays by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-59

Table 8: World 15-Year Perspective for Cell-Based Assays by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, and Rest of World Markets for Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) II-60
Cell-Based Assays Market by Application II-61
Table 9: World Recent Past, Current and Future Analysis for
Cell-Based Assays for Basic Research by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) II-61

Table 10: World Historic Review for Cell-Based Assays for
Basic Research by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-62

Table 11: World 15-Year Perspective for Cell-Based Assays for
Basic Research by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe, and Rest of World Markets
for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-63

Table 12: World Recent Past, Current and Future Analysis for
Cell-Based Assays for ADME Testing by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) II-64

Table 13: World Historic Review for Cell-Based Assays for ADME
Testing by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-65

Table 14: World 15-Year Perspective for Cell-Based Assays for
ADME Testing by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe, and Rest of World Markets
for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-66

Table 15: World Recent Past, Current and Future Analysis for
Cell-Based Assays for Drug Discovery by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) II-67

Table 16: World Historic Review for Cell-Based Assays for Drug
Discovery by Geographic Region - US, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-68

Table 17: World 15-Year Perspective for Cell-Based Assays for
Drug Discovery by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe, and Rest of World Markets
for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-69


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Cell-Based Assay Market to Witness Significant Growth III-1
Functional Cell Assays - A Key Segment III-1
Increased Usage Drives Growth of Cell-based Assays III-2
Impact of Automation & High-Throughput Screening on CBA Market III-2
Custom Designed Assays to Drive the US Cell-based Assay Market III-2
Clinical Trials Market in the US III-3
Competitive Scenario III-3
Table 18: Leading Players in the US Cell-Based Assays
Market (2013): Percentage Breakdown of Revenues for
Millipore, Promega, EMD Biosciences, BD Biosciences, New
England Biolabs and Others (includes corresponding
Graph/Chart) III-4
Product Launches III-4
Strategic Corporate Developments III-7
Focus on Select Players III-8
B.Market Analytics III-16
Table 19: US Recent Past, Current and Future Analysis for
Cell-Based Assays by Application - Basic Research, ADME
Testing and Drug Discovery Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2013
through 2020 (includes corresponding Graph/Chart) III-16

Table 20: US Historic Review for Cell-Based Assays by
Application - Basic Research, ADME Testing and Drug
Discovery Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-17

Table 21: US 15-Year Perspective for Cell-Based Assays by
Application - Percentage Breakdown of Dollar Sales for Basic
Research, ADME Testing and Drug Discovery Markets for Years
2006, 2014 and 2020 (includes corresponding Graph/Chart) III-18

2. JAPAN III-19
Market Analysis III-19
Table 22: Japanese Recent Past, Current and Future Analysis
for Cell-Based Assays by Application - Basic Research, ADME
Testing and Drug Discovery Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2013
through 2020 (includes corresponding Graph/Chart) III-19

Table 23: Japanese Historic Review for Cell-Based Assays by
Application - Basic Research, ADME Testing and Drug
Discovery Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-20

Table 24: Japanese 15-Year Perspective for Cell-Based Assays
by Application - Percentage Breakdown of Dollar Sales for
Basic Research, ADME Testing and Drug Discovery Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-21

3. EUROPE III-22
A.Market Analysis III-22
Current and Future Analysis III-22
Pharmaceutical Companies Opt for Cell-Based Assays in Drug
Discovery III-22
Rising Number of Drug Targets Surge Demand for Cell-Based
Assays III-22
GPCR Targets to Drive Growth in Functional Cell Assay Market III-23
Cell Growth-Based Assay Kits Market Makes Progress III-23
Cell Death Based Assays: Efficiency Improvements in
Development Programs Favor Growth III-23
Cell-based Assays Represent the Primary Drug Discovery Tool
in HTS Laboratories III-24
Advances in Technology, Identification Methods, and Lab
Disciplines in CBA Market III-24
Regulatory Requirements in Cell-Based Assays Market III-24
Validation Assays for Compliance with ICH Guidelines III-25
Outsourcing of Validation Studies to CTOs III-25
Growth of European Drug Discovery CRO Market: Opportunities
for CBA Market III-25
Clinical Trials Market in Europe III-26
Competitive Landscape III-26
Product Launches III-27
Strategic Corporate Developments III-28
Focus on Select Players III-30
B.Market Analytics III-33
Table 25: European Recent Past, Current and Future Analysis
for Cell-Based Assays by Geographic Region - France,
Germany, Italy, UK, Spain and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-33

Table 26: European Historic Review for Cell-Based Assays by
Geographic Region - France, Germany, Italy, UK, Spain and
Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2012
(includes corresponding Graph/Chart) III-34

Table 27: European 15-Year Perspective for Cell-Based Assays
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain and Rest of Europe
Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-35

Table 28: European Recent Past, Current and Future Analysis
for Cell-Based Assays by Application - Basic Research, ADME
Testing and Drug Discovery Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2013
through 2020 (includes corresponding Graph/Chart) III-36

Table 29: European Historic Review for Cell-Based Assays by
Application - Basic Research, ADME Testing and Drug
Discovery Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-37

Table 30: European 15-Year Perspective for Cell-Based Assays
by Application - Percentage Breakdown of Dollar Sales for
Basic Research, ADME Testing and Drug Discovery Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-38

4. REST OF WORLD III-39
A.Market Analysis III-39
Current and Future Analysis III-39
Emerging Nations Capitalize on the Outsourcing Trend III-39
China III-40
Life Sciences Market in China Continues to Thrive Despite
Recession III-40
China Emerges as the Major Outsourcer for Drug Discovery III-40
China Begins Implementation of GLP Standard III-41
Use of Non-Human Primates- A Key Feature of Chinese
Pharmaceutical Sector III-41
Going Ahead III-41
India III-42
A Thriving Clinical Trials Market III-42
Table 31: Cost of Conducting Clinical Trials: India Vs.
US (In US$ Million) (includes corresponding Graph/Chart) III-43
Strategic Corporate Developments III-43
B.Market Analytics III-44
Table 32: Rest of World Recent Past, Current and Future
Analysis for Cell-Based Assays by Application - Basic
Research, ADME Testing and Drug Discovery Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-44

Table 33: Rest of World Historic Review for Cell-Based
Assays by Application - Basic Research, ADME Testing and
Drug Discovery Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2012
(includes corresponding Graph/Chart) III-45

Table 34: Rest of World 15-Year Perspective for Cell-Based
Assays by Application - Percentage Breakdown of Dollar Sales
for Basic Research, ADME Testing and Drug Discovery Markets
for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-46


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 74 (including Divisions/Subsidiaries - 79)

The United States (47)
Japan (1)
Europe (29)
- France (3)
- Germany (6)
- The United Kingdom (10)
- Italy (1)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (2)

Download the full report: https://www.reportbuyer.com/product/552745/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com  
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cell-based-assays-market-300026375.html

SOURCE ReportBuyer